https://orcid.org/0000-0001-7401-2205
References
- Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the use of Real-World evidence in the regulatory process. Clin Pharmacol Ther. 2020;107(4):843–852.
- Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of Real-World clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
- 21st Century Cures Act. HR 34. 114th Congress 2015-2016. Available from: https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf
- Abraha I, Montedori A, Serraino D, et al. Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review. BMJ Open. 2018;8(7):e019264.
- Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from medicare claims data. J Clin Oncol. 2001;19(5):1455–1461.
- Lamont EB, Herndon JE, 2nd, Weeks JC, et al. Measuring clinically significant chemotherapy-related toxicities using medicare claims from cancer and leukemia group B (CALGB) trial participants. Med Care. 2008;46(3):303–308.
- Mendelsohn AB, Marshall J, McDermott CL, et al. Patient characteristics and utilization patterns of Short-Acting recombinant granulocyte Colony-Stimulating factor (G-CSF) biosimilars compared to their reference product. Drugs Real World Outcomes. 2021.
- Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40: IV55–IV61.
- Funch D, Ross D, Gardstein BM, et al. Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. BMC Health Serv Res. 2017;17(1):330.
- Lamont EB, Lan L. Sensitivity of medicare claims data for measuring use of standard multiagent chemotherapy regimens. Med Care. 2014;52(3):e15-20–e20.
- Lockhart CM, McDermott CL, Felix T, et al. Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: the biologics and biosimilars collective intelligence consortium experience. Pharmacoepidemiol Drug Saf. 2020;29(7):811–813.
- Lund JL, Sturmer T, Harlan LC, et al. Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care. 2013;51(5):e27-34–e34.
- Nordstrom BL, Whyte JL, Stolar M, et al. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):21–28.
- Warren JL, Mariotto A, Melbert D, et al. Sensitivity of medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care. 2016;54(8):e47-54–e54.
- Biologics and Biosimilars Collective Intelligence Consortium. www.bbcic.org
- NCCN Guidelines: Treatment by cancer type. 2022. https://www.nccn.org/guidelines/category_1
- Pawloski PA, McDermott CL, Marshall JH, et al. BBCIC research network analysis of First-Cycle prophylactic G-CSF use in patients treated with High-Neutropenia risk chemotherapy. J Natl Compr Canc Netw. 2021;:jnccn20268.
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin. 2019;69(5):363–385.
- Krzyzanowska MK, Enright K, Moineddin R, et al. Can Chemotherapy-Related acute care visits be accurately identified in administrative data? JOP. 2018;14(1):e51–e8.
- Ritzwoller DP, Carroll N, Delate T, et al. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care. 2013;51(10):e67-73–e73.
- Methotrexate Sodium - Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf
- McDermott CL, Engelberg RA, Woo C, et al. Novel data linkages to characterize palliative and End-Of-Life care: challenges and considerations. J Pain Symptom Manage. 2019;58(5):851–856.
- Cancer Treatment & Survivorship Facts & Figures 2019-2021. 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf
- Levinson KL, Bristow RE, Donohue PK, et al. Impact of payer status on treatment of cervical cancer at a tertiary referral center. Gynecol Oncol. 2011;122(2):324–327.
- Cancer Trends Proress Report. 2021. https://progressreport
- Doleh Y, Lal LS, Blauer-Petersen C, et al. Treatment patterns and outcomes in pancreatic cancer: retrospective claims analysis. Cancer Med. 2020;9(10):3463–3476.
- Leveridge MJ, Siemens DR, Brennan K, et al. Temporal trends in management and outcomes of testicular cancer: a population-based study. Cancer. 2018;124(13):2724–2732.
- Zakem SJ, Robin TP, Smith DE, et al. Evolving trends in the management of high-intermediate risk endometrial cancer in the United States. Gynecol Oncol. 2019;152(3):522–527.